Neuroprotective effects of statins: Evidence from preclinical and clinical studies

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 3, 2012, Pages 252-259

  Fisher, Marc ^a   Moonis, Majaz ^a  

^a University of Massachusetts   (United States)

Author keywords

Ischemic stroke; Neuroprotection; Stroke outcome; Therapy

Indexed keywords

ATORVASTATIN; COMPACTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE SYNTHASE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; ATHEROSCLEROSIS; BRAIN BLOOD FLOW; BRAIN EMBOLISM; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DYSPHAGIA; ENZYME ACTIVITY; EXCITOTOXICITY; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SECONDARY PREVENTION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

EID: 84865683317     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0174-9     Document Type: Article

References (45)

1. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated metaanalysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-63.
2. Prinz V, Endres M. Statins and stroke: prevention and beyond. Curr Opin Neurol 2011:75-80.
3. Goldstein LB. Statins and ischemic stroke severity: cytoprotection. Curr Athero Rep. 2009;11:296-300.
4. Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:2442-9.
5. Asahi M, Huang Z, Thomas S, et al. Protective effects of statins involve both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab. 2005;25:722-9. (Pubitemid 40705607)
6. Laufs U, Endres M, Stagliano NE, et al. Neuroprotection mediated by changes in endothelial actin cytoskeleton. J Clin Invest. 2000;106:15-24. (Pubitemid 30437236)
7. Endres M, Laufs U, Liao JK, Moskowitz MA. Targeting eNOS for stroke protection. Trends Neurosci. 2004;27:283-9. (Pubitemid 38529957)
8. Zaccoo A, Togo J, Spence K, et al. 3-Hydorxy-3- methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitoxicity. J Neurosci. 2003;23:1104-11.
9. Johnson-Anuna LN, Eckert GP, Franke C, et al. Simvastatin protects neurons from cytotoxicity by upregulating Bcl-2 mRNA and protein. J Neurochem. 2007;101:77-86. (Pubitemid 46426484)
10. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and ophenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J Clin Invest. 1997;100:2671-9. (Pubitemid 28007534)
11. Kureishi Y, Luo Z, Shiojima I, et al. The HMGCoA reductase inhibitor simvastatin activates protein kinase Akt and promotes angiogenesis in normocholeterolemic animals. Nat Med. 2000;6:1004-10.
12. Ovbiagele B, Saver JL, Starkman S, et al. Statin enhancement of collateralization in acute stroke. Neurology. 2007;68:2129-31. (Pubitemid 46912132)
13. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone-marrow derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405. (Pubitemid 32730786)
14. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743-51. (Pubitemid 36622511)
15. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95:8880-5. (Pubitemid 28350583)
16. Kawashima S, Yamashita T, Miwa Y, et al. HMG-CoA reductase inhibitor has protective effects against stroke events in spontaneously hypertensive rats. Stroke. 2003;34:157-63. (Pubitemid 36070817)
17. Cakama A, Yemisci M, Koksoy C, et al. Statin pretreatment protects brain against focal cerebral ischemia in diabetic mice. J Surg Res. 2007;138(2):254-8. (Pubitemid 46365720)
18. Sironi L, Cimino M, Guerrini U, et al. Treatment with a statin after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscel Thromb Vasc Biolf. 2003;23:322-7. (Pubitemid 36231947)
19. Kilic U, Bassetti CL, Kilic E, et al. Post-ischemic delivery of the 3-hydorxy-3-methylglutaryl coenzyme reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular regulated kinase 1/-2. Neuroscience. 2005;134:901-6. (Pubitemid 41133393)
20. Prinz V, Laufs U, Gertz K, et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke. 2008;39:433-8. (Pubitemid 351619468)
21. Zhang LI, Chopp M, Jia L, et al. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab. 2009;29:1816-24.
22. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Int Med. 2003;163:669-76. (Pubitemid 36343359)
23. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hy-pertensive patients who have average or lower-thanaverage cholesterol concentrations, in the angloscandinavian cardiac outcomes trial - lipid lowering arm (ascot-lla): a multicentre randomised controlled tria. Lancet. 2003;361:1149-58. (Pubitemid 36398384)
24. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121, 000 patients. Am J Med. 2008;121:24-33.
25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4s) Lancet 1994;344:1383-1389
26. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med. 1995;333:1301-7.
27. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the cholesterol and recurrent events (care) study. The care investigators. Circulation. 1999;99:216-23. (Pubitemid 29056362)
28. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000;343:317-26. (Pubitemid 30616697)
29. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase z of the a to z trial. JAMA. 2004;292:1307-16. (Pubitemid 39223221)
30. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (prosper): a randomised controlled trial. Lancet. 2002;360:1623-30. (Pubitemid 35379733)
31. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation. 1995;92:2419-25.
32. MRC/bhf heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;360:7-22
33. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59. (Pubitemid 44202151)
34. Goldstein LB, Amarenco P, Zivin J, et al. Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (sparcl) trial. Stroke. 2009;40:3526-31.
35. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195-207.
36. Ford AL, An H, D'Angelo G, et al. Preexisting statin use is associated with greater reperfusion in hyperacute ischemic stroke. Stroke; J Cereb Circ. 2011;42:1307-13.
37. Birnbaum Y, Lin Y, Ye Y, Merla R, Perez-Polo JR, Uretsky BF. Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharm Ther. 2008;13:72-9. (Pubitemid 351246258)
38. Moonis M, Fisher M. HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. Exp Rev Neurotherap. 2004;4:241-7. (Pubitemid 38315944)
39. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. Hmg-coa reductase inhibitors improve acute ischemic stroke outcome. Stroke. 2005;36:1298-300. (Pubitemid 40798758)
40. Stead LG, Vaidyanathan L, Kumar G, et al. Statins in ischemic stroke: just low-density lipoprotein lowering or more? J Stroke Cerebrovasc. 2009;18:124-7.
41. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69:904-10. (Pubitemid 47329591)
42. Biffi A, Devan WJ, Anderson CD, Cortellini L, Furie KL, Rosand J, Rost NS. Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. Stroke. 2011;42:1314-9.
43. Ni Chroinin D, Callaly EL, Duggan J, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the north dublin population stroke study. Stroke. 2011;42:1021-9.
44. Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43:147-54.
45. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. Stroke. 2011;42:227-76.